38. Role of High Mobility Group Box-1 (HMGB1) in Obesity and Metabolic Syndrome
Rabea Nasir1, Usman Nasir2, Ghazala Khalid3, Rashid Siddique4, Nimra Ikram2 and Akmal Khurshid Bhatti2
ABSTRACT
Objective: To determine the role of hmgb1 in obesity and metabolic syndrome.
Study Design: Experimental study
Place and Duration of Study: This study was conducted at the Mohammad Islam Medical College Gujranwala and Sialkot Medical College Sialkot during Jan 2019 to March 2020.
Materials and Methods: 40 blood samples of adults Metabolic syndrome (MS) subjects and 20 samples of obese subjects between the ages 25-50 were obtained from M. Islam Teaching Hospital, Gujranwala and Sialkot Medical College Sialkot. 20 healthy subjects served as the control group. Fasting serum samples were analyzed for lipid profile, fasting blood glucose (FBG), and insulin and HMGB1 levels. Insulin and HMGB1 were estimated by commercially available ELISA kits. Insulin resistance was calculated by HOMA-IR index.
Results: Blood pressure showed significant differences among the three groups of subjects and was shown to be highest in the MS group. Significantly increased levels of FBS (124.13±8.77 mg/dl) were observed in the MS group as compared to obese and normal subjects (85.95±2.68 mg/dl and 84.50±1.06 mg/dl, respectively). Lipid profile revealed that triglycerides, LDL and cholesterol levels were significantly higher (213.78 ± 11.62mg/dl, 133.30 ± 6.45mg/dl and 218.98 ± 5.66mg/dl respectively) and HDL levels were relatively low in MS patients (44.18 ± 1.03) in comparison with obese triglycerides, LDL, cholesterol and HDL levels (133.85±6.31mg/dl, 106.15±4.31mg/dl, 166.00±5.56 mg/dl and 45.70±1.53mg/dl respectively) and normal subjects triglycerides, LDL, cholesterol and HDL levels(122.05±4.25mg/dl, 108.05 ± 3.56mg/dl, 152.15±6.00mg/dl and 46.65±1.07mg/dl respectively). Mean HMGB1 levels were maximal in patients with MS (19.68±2.58 mg/dl) and were significantly different from mean levels in subjects with obesity alone (11.06±1.12 mg/dl) and healthy subjects (13.28±0.65 mg/dl). Significantly elevated levels of insulin and insulin resistance were evident in patients suffering from MS (13.59±1.49 mg/dl and 4.06±0.54 mg/dl, respectively) as compared to healthy subjects (10.22±1.29 mg/dl and 2.13±0.26 mg/dl, respectively) and the obese group (9.95 ± 1.67 mg/dl and 2.06±0.32 mg/dl, respectively).
Conclusion: The current study demonstrates significantly higher levels of serum HMGB1 levels in MS patients in comparison with those of obese and control groups. The study suggests a role of HMGB1 as a pro-inflammatory cytokine in patients with MS. Significantly increased insulin resistance in MS patients further indicates that the HMGB1 related inflammatory pathway may be involved in pathogenesis of diabetes type 2.
Key Words: HMGB1, Metabolic syndrome (MS), obesity, insulin resistance, pro-inflammatory cytokine
Citation of article: Nasir R, Nasir U, Khalid G, Siddique R, Ikram N, Bhatti AK. Role of Hmgb1 in Obesity and Metabolic Syndrome. Med Forum 2020;31(12):161-165.